^
Association details:
Evidence:
Evidence Level:
Sensitive: B - Late Trials
Source:
Title:

Patient reported outcomes (PROs) with 1L durvalumab (D), with or without tremelimumab (T), plus chemotherapy (CT) in metastatic (m) NSCLC: Results from POSEIDON

Published date:
03/23/2022
Excerpt:
Pts (n=1013) with EGFR/ALK wild-type mNSCLC were randomised (1:1:1)….Improvement rates in PROs, including prespecified symptoms/domains of interest, were greater for T + D + CT and D + CT vs CT alone....The addition of D (+/- T) to CT improved efficacy while delaying deterioration in health-related QoL in pts with mNSCLC. Pts in the T + D + CT and D + CT arms tended to have longer TTD and greater rates of improvement in global health status/QoL, functioning and symptoms vs pts in the CT arm.
Secondary therapy:
Chemotherapy
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC

Excerpt:
...Documented EGFR and ALK wild-type status (local or central)....
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer (PACIFIC 8)

Excerpt:
...Documented EGFR and ALK wild-type status (local or central). ...
More C2 evidence
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

A multicentric Phase II, open-label study evaluating the efficacy of the combination of hypofractionated stereotactic radiation therapy with the anti-PDL1 immune checkpoint inhibitor Durvalumab in NSCLC patients with 1 to 4 Brain Metastases. Etude de phase II multicentrique en ouvert évaluant l'efficacité de l'association d'une radiothérapie hypofractionnée en conditions stéréotaxiques et de l'inhibiteur de checkpoint immunitaire anti-PDL1 durvalumab chez des patients porteurs de 1 à 4 métastases cérébrales de CBNPC.

Excerpt:
...1.Histologically or cytologically confirmed non-small cell lung cancer (NSCLC) 2.Stage IV metastatic disease with intra-cranial progressive disease documented by MRI evidence 3.Patient with 1 to 4 brain metastases (< 3.5 cm on T1 post-gadolinium sequence) all amenable to hFSRT, with at least 1 metastasis ≥ 1 cm (RANO-BM criteria evaluation) 4.Patient with no evidence of extra-cranial progressive disease on 18-FDG PET-CT 5.Patient with wild type EGFR and ALK 6.Age ≥ 18 years at time of study entry 7.ECOG performance status < 2 i.e. 0 or 1 8.Body weight >30kg 9.Life expectancy of at least 3 months 10.Previously treated patients even with immunotherapy are accepted 11.Adequate Hematology laboratory data within 6 weeks prior to start of treatment: Absolute neutrophils> 1.5 x 109/L, u2028Platelets ≥ 100 x 109/L, u2028Hemoglobin ≥ 9 g/dL 12.Adequate Biochemistry laboratory data within 6 weeks prior to start of treatment: Total bilirubin ≤ 1.5 x ULN (except patient with confirmed Gilbert's syndrome or liver metastasis: Total bilirubin ≤ 3 X ULN), Transaminases ≤ 2.5 x ULN, Alkalin phosphatases ≤ 5 x ULN, Creatinine clearance > 40 mL/min (Cockcroft) 13.Patients who have received prior anti–PD-1, anti PD-L1 or anti CTLA-4 are accepted, if the following conditions are completed: -All AEs while receiving prior immunotherapy must have completely resolved or resolved to baseline prior to screening for this study -Must not have experienced a ≥Grade 3 immune related AE or an immune related neurologic or ocular AE of any grade while receiving prior immunotherapy. ...
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)

Excerpt:
...- EGFR and ALK wild-type....
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

A Trial Evaluating Stereotactic Radiotherapy Plus Durvalumab Continuation for Patients With NSCLC Metachronous Oligometastatic Disease Under Durvalumab Consolidation Following Chemoradiation

Excerpt:
...Patient with wild type EGFR and ALK 12....
Trial ID:
Less C2 evidence
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Association of the Benefit of Durvalumab Consolidation Therapy and Driver Mutation Status for Locally Advanced Non-small Lung Cancer

Published date:
08/08/2023
Excerpt:
In this report, we examined the efficacy of durvalumab for patients with locally advanced, unresectable NSCLC at our institution. In addition, we focused on its efficacy in patients with driver mutations....In this retrospective analysis, durvalumab consolidation therapy following definitive chemoradiotherapy had a tendency to improve median PFS(group A 664 days [436-1069, 95%CI] vs group B 377days [282-451, 95%CI] p=0.053). The subgroup analysis of patients without driver mutations of EGFR, ALK or ROS-1 showed statistically longer median PFS by durvalumab consolidation (695 days [575-NA, 95%CI] vs 382 days [282-488, 95%CI], p<0.05)....